[Immune responses and clinical effects of OK-432 immunotherapy in lung neoplasms].
D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation / Q000187:drug effects; D010844:Picibanil / Q000627:therapeutic use*
D001688:Biological Products; D010844:Picibanil